3:15 PM - 3:30 PM (PDT), Monday, June 13, 2022
Genomenon’s AI-driven genomic engine leverages billions of genetic associations between diseases, phenotypes, and therapies found within the medical evidence. They deliver a comprehensive genomic landscape for every disease, including rare, neurodegenerative, and genetic diseases, as well as somatic and germline cancer.
Armed with a comprehensive base of molecular biomarkers and disease mechanisms, Genomenon’s customers expand their genetic knowledge of the disease drivers by a factor of 10-20X to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Prodigy Genomic Landscape
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Founder, CSO